Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate‐to‐severe hidradenitis suppurativa

Abstract

Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-tosevere hidradenitis suppurativa Dear Editor, Atopic dermatitis (AD) is a chronic immune-mediated inflammatory skin disorder presenting with eczematous recurrent lesions and severe pruritus and associating with significant morbidity and poor quality of life. Treatment options include oral corticosteroids, cyclosporine, phototherapy, janus kinase inhibitor (upadacitinib), and dupilumab, which is the only biologic EMA approved for moderate to severe AD. 1 Hidradenitis suppurativa (HS) is a debilitating chronic cutaneous disease, characterized by painful nodules, abscess, and sinus tracts distributed in the intertriginous areas. Medical approaches are F I G U R E 1 (A and B) HS involving the groin and the inguinal fold, before starting treatment with dupilumab. (C-E) Clinical images of atopic eczema before starting treatment with dupilumab. (F and G) HS in clinical remission after 6 months of dupilumab therapy. (H-J) Atopic eczema after 6 months of dupilumab therapy

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

“…Three cases of patients with hidradenitis suppurativa (HS) and concomitant AD showed remission of the previously uncontrolled HS after having failed systemic antibiotics and in one case adalimumab ( Table 8 ) [ 264 , 265 , 266 ]. High AD-disease activity might impose an additional trigger to flares of HS, however, HS itself is mainly associated with Th1/Th17-responses.…”

Is Exploration of Alternate Immune Pathways Needed in Hidradenitis Suppurativa? A Case of Atopic Dermatitis and Concurrent Hidradenitis Suppurativa Responding to Dupilumab

“…Searching the PubMed database revealed only two case letters on the successful use of dupilumab in a patient with AD and concomitant HS [ 20 , 21 ]. Many other biologics are being studied for the treatment of HS; however, it seems that dupilumab is not one of them.…”

Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review

“…2020 [ 31 ], Molinelli et al. 2022 [ 32 ] Anakinra IL-1R Tzanetakou et al. 2016 [ 33 ], Zarchi et al.…”

“…One case reported ≥ 50% reduction in HS inflammatory lesion count and no increase in abscesses or draining fistulas compared with baseline after 4 months of dupilumab treatment [ 31 ]. Another case of a patient with frequent HS exacerbation and failure of systemic antibiotics reported no HS and AD exacerbation during 6 months of dupilumab treatment [ 32 ].…”

“…Kaakati et al 2021 [30], Gambardella et al 2020[31],Molinelli et al 2022 [32] Anakinra IL-1RTzanetakou et al 2016 [33], Zarchi et al 2013 [34], Menis et al 2015 [35], Russo et al 2016 [36], Andre ´et al 2019 [37], Leslie et al 2014 [38] Pyoderma gangrenosum Ixekizumab IL-17 Kao et al 2022 [45], Gul et al 2020 [46], Pollack et al 2021 [47] Secukinumab IL-17 McPhie et al 2020 [48], Coe et al 2022 [49], Li et al 2022 [50], Nikolakis et al 2021 [51], Toussi et al 2020 [52], Moreno Garcı ´a et al 2019 [53], Jin et al 2019 [54], Pinard et al 2018 [55], Wollina et al 2020 [56] Risankizumabrzaa IL-23 Weigelt et al 2021 [57], Burgdorf et al 2020 [58], Orita et al 2022 [59] Tildrakizumabasmn IL-23 John et al 2020 [60], Kok et al 2020 [61] Guselkumab IL-23 Reese et al 2022 [62], Baier et al 2021 [63]…”